05858nam 2201573z- 450 991056647180332120231214133446.0(CKB)5680000000037662(oapen)https://directory.doabooks.org/handle/20.500.12854/81021(EXLCZ)99568000000003766220202205d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierEndothelial Dysfunction: From Pathophysiology to Novel Therapeutic ApproachesBaselMDPI - Multidisciplinary Digital Publishing Institute20221 electronic resource (368 p.)3-0365-3036-3 3-0365-3037-1 Dear colleagues, This Special Issue, “Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches”, focuses on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions. Vascular endothelium is an active tissue and plays a crucial role in the maintenance of vascular homeostasis. Chronic exposure to risk factors, such as hypertension, high cholesterolemia, or oxidative stress, induces endothelial dysfunctions and results in a loss of endothelial integrity, smooth muscle cell proliferation, and macrophage recruitment. The pathophysiology of endothelial dysfunction (ED) is complex and multi-factorial factors are involved, such as oxidative stress or chronic inflammation. The primary prevention of cardiovascular risk factors and endothelial dysfunctions, as well as the early detection of or molecular imaging techniques for endothelial dysfunction, helps to prevent the development of cardiovascular disorders. Novel therapeutic approaches or drug delivery systems for endothelial dysfunctions have had promising beneficial effects in preclinical or clinical levels by affecting the progression of atherosclerotic changes, tumor angiogenesis, and host–immune reactions near tumor environments.Endothelial DysfunctionTechnology: general issuesbicsscBiotechnologybicsscendothelial cellsoxidative stressinflammageingendothelial dysfunctionaldehyde dehydrogenase-2cardiovascular diseaseneurovascular diseasevascular inflammationAPE1/Ref-1cardiovascular diseasessubcellular localizationserological biomarkersatherosclerosisaerobic exercisePCSK9LOX-1insulin resistancemacrophage polarityserum γ-glutamyltransferaseessential hypertensioncardiovascular risk factorsangiogenesisnargenicin A1compound 9VEGFVEGFR2HIF-1αelectronegative low-density lipoproteinLDL(-)L5 LDLoxidized LDLoxLDLADMAargininearginine paradoxBH4blood pressureCOVID-19dietary supplementsendotheliumeNOS uncouplingheart failurehypertensionL-argininemyocardial infarctionNADPHnitric oxideperipheral artery diseaseApoE knockout mouseatorvastatinVCAM-1galectin-3neutrophil/lymphocyte ratioelectronegative LDLLDL(−)lectin-like oxLDL receptor-1dyslipidemiachronic venous insufficiencyprolyl oligopeptidase (POP)inflammationendothelial disfunctionlung diseaseendothelial to mesenchymal transitionpulmonary hypertensionpulmonary fibrosismetformindiabetesCV riskhyperglycemiaglycated lipoproteinsglycated LDLglycated HDLendothelial cell dysfunctionmolecular mechanismsepigenetic factorstherapeutic approachesvasoactive factorsEndoMTTGF-βepigeneticsendothelial cellglycolysismetabolismpathological angiogenesistumor microenvironmentMRI (magnetic resonance imaging)high-fat dietsplaque burdenlow-level laser therapyphototherapyvascular diseasehealingischemiavascular calcificationchronic kidney diseaseCKDuremic toxinshyperphosphatemiavascular smooth muscle cellsVSMCsmacrophagesTechnology: general issuesBiotechnologyJeon Byeong Hwaedt1319556Jeon Byeong HwaothBOOK9910566471803321Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches3033962UNINA